WD Rutherford LLC Buys 3,599 Shares of Boston Scientific Corporation (NYSE:BSX)

WD Rutherford LLC raised its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 63.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 9,245 shares of the medical equipment provider's stock after buying an additional 3,599 shares during the period. WD Rutherford LLC's holdings in Boston Scientific were worth $871,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Colonial Trust Co SC lifted its holdings in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares in the last quarter. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific during the fourth quarter worth $25,000. Sunbeam Capital Management LLC bought a new stake in Boston Scientific in the 4th quarter valued at $26,000. Ameriflex Group Inc. acquired a new position in Boston Scientific in the 4th quarter worth $31,000. Finally, Fairway Wealth LLC bought a new position in Boston Scientific during the 4th quarter worth about $36,000. Institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. BTIG Research reaffirmed a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Truist Financial boosted their price target on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $116.09.

Boston Scientific Trading Down 0.4%

BSX traded down $0.37 during midday trading on Wednesday, hitting $101.36. 5,188,625 shares of the company were exchanged, compared to its average volume of 6,586,234. The firm's 50 day moving average price is $101.35 and its 200-day moving average price is $98.89. Boston Scientific Corporation has a 1-year low of $71.88 and a 1-year high of $107.17. The firm has a market capitalization of $149.96 billion, a P/E ratio of 73.99, a P/E/G ratio of 2.63 and a beta of 0.68. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the business earned $0.56 EPS. The company's revenue was up 20.9% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.